Denmark's Netcompany has been awarded a five-year contract from NHS England, worth more than £215 million, to build the ...
Shares in China's Hutchmed surged today after GSK paid $110 million upfront for rights to a preclinical-stage KRAS and EGFR-targeted drug with potential in colorectal, pancreatic, and lung cancer.
Shares in rare disease specialist Ultragenyx lost nearly 47% of their value after the announcement, more than wiping out ...
Boehringer Ingelheim has joined Sanofi and AstraZeneca in signing up to deploy Owkin's AI platform K Pro in its drug ...
The US Advanced Research Projects Agency for Health (ARPA-H) has awarded $125 million in funding, split across five groups, ...
Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...
The US FDA issued similar warning letters to five different online peptide vendors on 24th August, giving the companies 15 ...
MHRA's first two centralised programmes are focusing on software or AI used as a medical device (SaMD/AIaMD) and the use of ...
Custom autologous cell therapies face immense manufacturing bottlenecks, steep financial costs, and vein-to-vein logistical ...
PMV Pharma is preparing to file for approval of its oral p53 protein reactivator drug rezatopopt in the first quarter of 2027 ...
Novartis has paused eight clinical trials of its experimental CAR-T therapy rapcabtagene autoleucel (rap-cel or YTB323) after ...
GSK is planning to start a phase 3 trial of the new vaccine later this month, saying it will be the first late-stage trial of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results